Heart and Vessels

, Volume 29, Issue 5, pp 611–618 | Cite as

Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty

  • Yelena Parfyonova
  • Irina Alekseeva
  • Olga Plekhanova
  • Alexander Deev
  • Elena Titaeva
  • Anatoly Dobrovolsky
  • Zufar Gabbasov
  • Anatoly Lyakishev
  • Vsevolod Tkachuk
Original Article
First Online:
Received:
Accepted:
  • 142 Downloads

Abstract

This study evaluates the predictive value of several biochemical indices of the coagulation–fibrinolysis system, platelet function, and inflammatory state for angina recurrence after successful percutaneous transluminal coronary angioplasty (PTCA). We measured preprocedural and follow-up plasma levels of C-reactive protein (CRP), fibrinogen, and urokinase plasminogen activator antigen (uPA), plasminogen activator inhibitor-1 (PAI-1) activity, tissue plasminogen activator activity, and adenosine diphosphate-induced platelet aggregation in 53 patients with chronic stable angina who underwent successful elective PTCA of single hemodynamically significant lesions in coronary arteries. All patients were followed up for 12 months after PTCA. The Cox proportional hazards model was used to assess the association of variables with angina recurrence rate. At the end of the follow-up, 16 patients had angina recurrence. Among 36 clinical, biochemical, and angiographic variables, the duration of stable angina more than 12 months before PTCA (χ 2 = 5.73; P = 0.02, hazard ratio (HR) 3.7, 95 % confidence interval (CI) 1.26–10.6), high baseline levels of CRP (>7 mg/l) (χ 2 = 8.34; P = 0.004, HR 2.9, 95 % CI 1.4–5.9), uPA antigen baseline (>1 ng/ml) (χ 2 = 17.11; P = 0.0001, HR 11.5, 95 % CI 3.6–36.7) and 48 h after PTCA (χ 2 = 15.73; P = 0.0001, HR 8.8, 95 % CI 3.01–25.96), baseline PAI-1 activity (>18 IU/ml) (χ 2 = 9.37; P = 0.002, HR 7.6, 95 % CI 2.07–27.84) were significant predictors of recurrent angina by univariate analyses. According to stepwise multivariate analyses, only the levels of plasma uPA antigen and serum CRP were shown to be significant independent predictors of angina recurrence (multivariate uPA χ 2 = 8.22, P = 0.004, HR 6.2, 95 % CI 1.78–21.67; CRP χ 2 = 4.09, P = 0.04, HR 1.9, 95 % CI 1.02–3.68). High preprocedural plasma uPA and serum CRP levels are indicative of angina recurrence after successful PTCA, and are valuable for the prognosis of restenosis.

Keywords

Angioplasty Angina recurrence Restenosis C-reactive protein Urokinase plasminogen activator 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This study was supported by grants from the Russian Academy of Sciences (no. 11-04-01925-a, 12-04-31954).

References

  1. 1.
    Bhoday J, de Silva S, Xu Q (2006) The molecular mechanisms of vascular restenosis: which genes are crucial? Curr Vasc Pharmacol 4:269–275PubMedCrossRefGoogle Scholar
  2. 2.
    Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wòjcik J, Sim KH, Tijssen JG, de Winter RJ, e-HEALING investigators, (2012) Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous™ Bio-engineered R stent™: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. Heart Vessels 27(4):360–369PubMedCrossRefGoogle Scholar
  3. 3.
    Biasucci LM (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110:e560–e567PubMedCrossRefGoogle Scholar
  4. 4.
    Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM (1999) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 100:1616–1622PubMedCrossRefGoogle Scholar
  5. 5.
    Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46:1820–1826PubMedCrossRefGoogle Scholar
  6. 6.
    Ikeda U, Hojo Y, Shimada K (2000) Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 102:E167PubMedCrossRefGoogle Scholar
  7. 7.
    Krasnikova TL, Parfyonova Y, Alekseeva IA, Arefieva TI, Mukhina SA, Dobrovolsky AB, Titaeva Y, Lyakishev AA, Resink TJ, Erne P, Tkachuk VA (1999) Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin Exp Pharmacol Physiol 26:354–357PubMedCrossRefGoogle Scholar
  8. 8.
    Gabbasov Z, Parfyonova Y, Popov E, Gavrilov I, Anuchin V, Dubov P, Djakonova Y (1998) Association of platelet function in hypertensive patients with left ventricular hypertrophy, transient myocardial ischemia, and coronary artery disease. Platelets 9:191–195PubMedCrossRefGoogle Scholar
  9. 9.
    Tkachuk VA, Plekhanova OS, Parfyonova YV (2009) Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 87:231–251PubMedCrossRefGoogle Scholar
  10. 10.
    Christ G, Kostner K, Zehetgruber M, Binder BR, Gulba D, Huber K (1999) Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J Thromb Thrombolysis 7:277–285PubMedCrossRefGoogle Scholar
  11. 11.
    Fornitz GG, Nielsen P, Amtorp O, Kassis E, Abildgard U, Sloth C, Winther K, Orskov H, Dalsgard J, Husted S (2001) Impaired fibrinolysis determines the outcome of percutaneous transluminal coronary angioplasty (PTCA). Eur J Clin Invest 31:586–592PubMedCrossRefGoogle Scholar
  12. 12.
    Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A (1996) Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 131:1–6PubMedCrossRefGoogle Scholar
  13. 13.
    Garg N, Fay WP (2007) Plasminogen activator inhibitor-1 and restenosis. Curr Drug Targets 8:1003–1006PubMedCrossRefGoogle Scholar
  14. 14.
    Katsaros KM, Speidl WS, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G (2008) Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents. J Thromb Haemost 6:508–513PubMedCrossRefGoogle Scholar
  15. 15.
    Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF (2001) Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 104:181–186PubMedCrossRefGoogle Scholar
  16. 16.
    Alaigh P, Hoffman CJ, Korlipara G, Neuroth A, Dervan JP, Lawson WE, Hultin MB (1998) Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 18:1281–1286PubMedCrossRefGoogle Scholar
  17. 17.
    Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES (1995) Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15:1432–1443PubMedCrossRefGoogle Scholar
  18. 18.
    Plekhanova O, Parfyonova Y, Bibilashvily R, Domogatskii S, Stepanova V, Gulba DC, Agrotis A, Bobik A, Tkachuk V (2001) Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 159:297–306PubMedCrossRefGoogle Scholar
  19. 19.
    Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D (1997) Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 81:829–839PubMedCrossRefGoogle Scholar
  20. 20.
    Plekhanova OS, Parfyonova YV, Bibilashvily RS, Stepanova VV, Erne P, Bobik A, Tkachuk VA (2000) Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 18:1065–1069PubMedCrossRefGoogle Scholar
  21. 21.
    Plekhanova O, Berk BC, Bashtrykov P, Brooks AI, Tkachuk V, Parfyonova Y (2009) Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res 46:177–187PubMedCrossRefGoogle Scholar
  22. 22.
    Parfyonova Y, Plekhanova O, Solomatina M, Naumov V, Bobik A, Berk B, Tkachuk V (2004) Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury. J Vasc Res 41:268–276PubMedCrossRefGoogle Scholar
  23. 23.
    Simon DI (2012) Inflammation and vascular injury: basic discovery to drug development. Circ J 76:1811–1818PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Degoma EM, Dunbar RL, Jacoby D, French B (2013) Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227:172–177PubMedCrossRefGoogle Scholar
  25. 25.
    Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M (2004) A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 173:285–290PubMedCrossRefGoogle Scholar
  26. 26.
    Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462–466PubMedCrossRefGoogle Scholar
  27. 27.
    Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G (1995) Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374–379PubMedGoogle Scholar
  28. 28.
    Laframboise WA, Dhir R, Kelly LA, Petrosko P, Krill-Burger JM, Sciulli CM, Lyons-Weiler MA, Chandran UR, Lomakin A, Masterson RV, Marroquin OC, Mulukutla SR, McNamara DM (2012) Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med 10:157PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Xu HY, Qiao SB, Zhang JF, Dong QT, Li JJ (2012) Different impacts of C-reactive protein and lipid profile on coronary lesions following a percutaneous coronary intervention. Coron Artery Dis 23:181–187PubMedCrossRefGoogle Scholar
  30. 30.
    Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW (2012) Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol 35:482–489PubMedCrossRefGoogle Scholar
  31. 31.
    Yano H, Horinaka S, Yagi H, Ishimitsu T (2013) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis. Heart Vessels 28(3):308–315PubMedCrossRefGoogle Scholar
  32. 32.
    Grad E, Danenberg HD (2013) C-reactive protein and atherothrombosis: cause or effect? Blood Rev 27:23–29PubMedCrossRefGoogle Scholar
  33. 33.
    Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ (2009) C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 120(20):1987–1995PubMedCrossRefGoogle Scholar
  34. 34.
    Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S, Engstrøm T, Saunamäki K, Jørgensen E, Holmvang L, Clemmensen P (2011) Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am J Cardiol 107(11):1597–1603PubMedCrossRefGoogle Scholar
  35. 35.
    Jeong HC, Ahn Y, Hong YJ, Kim JH, Jeong MH, Kim YJ, Chae SC, Cho MC; Other KAMIR (Korea Acute Myocardial Infarction Registry) Investigators (2012) Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. Int J Cardiol. doi: 10.1016/j.ijcard.2012.04.123
  36. 36.
    Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208–3214PubMedCrossRefGoogle Scholar
  37. 37.
    Benchimol D, Dubroca B, Dufourq P, Benchimol H, Couffinhal T, Dartigues JF, Bonnet J (1997) Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events. Int J Cardiol 60:201–211PubMedCrossRefGoogle Scholar
  38. 38.
    Price JF, Mamode N, Smith FB, Woodburn KR, Rumley A, Lowe GD, Fowkes FG (1997) Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 14:392–398PubMedCrossRefGoogle Scholar
  39. 39.
    Le BH, Plow EF, Topol EJ (1996) Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 28:1643–1651CrossRefGoogle Scholar
  40. 40.
    Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A (1997) Postangioplasty restenosis: platelet activation and the coagulation–fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133:387–392PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Yelena Parfyonova
    • 1
  • Irina Alekseeva
    • 2
  • Olga Plekhanova
    • 3
  • Alexander Deev
    • 4
  • Elena Titaeva
    • 5
  • Anatoly Dobrovolsky
    • 5
  • Zufar Gabbasov
    • 6
  • Anatoly Lyakishev
    • 2
  • Vsevolod Tkachuk
    • 3
  1. 1.Laboratory of AngiogenesisCardiology Research CenterMoscowRussia
  2. 2.Department of AtherosclerosisCardiology Research CenterMoscowRussia
  3. 3.Laboratory of Molecular EndocrinologyCardiology Research CenterMoscowRussia
  4. 4.National Research Center for Preventive MedicineMoscowRussia
  5. 5.Department of AngiologyCardiology Research CenterMoscowRussia
  6. 6.Laboratory of Stem CellsCardiology Research CenterMoscowRussia

Personalised recommendations